Randomized Trials Meet Real-World Evidence in the Era of Combination CKD Therapies

Read full text Summarise with VIRAT
Authors: Roberto Pecoits-Filho, Andréa Carla Bauer
Cited by: 0
References: 11

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Chronic kidney disease (CKD) in type 2 diabetes (T2D) is no longer managed with a single therapeutic option. Instead, treatment increasingly relies on layered combination of renin–angiotensin system inhibitors (RASi), sodium–glucose cotransporter-2 inhibitors (SGLT2i), non-steroidal mineralocorticoid receptor antagonists (nsMRA), and an expanding group of cardio-kidney-metabolic (CKM) therapies.1-4 Clinical practice guidelines have evolved rapidly as randomized trials have demonstrated the benefits of these agents, and defining these as guideline-directed medical therapies (GDMTs) in CKD and T2D.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Diabetes Treatment and Management Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
5
Pages
106519–106519
Publication date
30 March 2026
Language
EN